This application relates generally to medical treatment systems and, more particularly, but not by way of limitation, to reduced pressure dressings, systems, and methods for treating linear wounds.
Clinical studies and practice have shown that providing a reduced pressure in proximity to a tissue site may augment and accelerate the growth of new tissue at the tissue site. The applications of this phenomenon are numerous, but application of reduced pressure has been particularly successful in treating wounds. This treatment (frequently referred to in the medical community as “negative pressure wound therapy,” “reduced pressure therapy,” or “vacuum therapy”) may provide a number of benefits, which may include faster healing and increased formulation of granulation tissue. Typically, reduced pressure is applied to tissue through a porous pad or other manifold device. The porous pad may distribute reduced pressure to the tissue and channel fluids that are drawn from the tissue.
According to an illustrative embodiment, provided is a system for treating a tissue site that may include a dressing assembly and a reduced-pressure source. The dressing assembly may include a dressing bolster, a comfort layer, a first sealing member, a second sealing member, and a sealing ring. The dressing bolster may have a first side and a second side. The comfort layer may be coupled to the second side of the dressing bolster. The first sealing member may cover the first side of the dressing bolster. The second sealing member may cover a portion of the second side of the dressing bolster and extend outward from the dressing bolster to form a drape extension. A portion of the first sealing member may be coupled to the second sealing member. The sealing ring may be disposed adjacent to the second side of the dressing bolster and may be comprised of a hydrocolloid including an absorbent. The first sealing member, the second sealing member, and the sealing ring may be configured to provide a sealed space over the tissue site. The reduced-pressure source may be configured to be coupled in fluid communication with the sealed space.
According to another illustrative embodiment, provided is a system for treating a tissue site that may include a dressing assembly, a sealing member, and a reduced-pressure source. The dressing assembly may include a dressing bolster, a comfort layer, and a sealing ring. The dressing bolster may have a first side and a second side. The comfort layer may have a first side and a second side, and the first side of the comfort layer may be coupled to the second side of the dressing bolster. The sealing ring may be coupled to the second side of the comfort layer, and the sealing ring may include an absorbent. The sealing member may be configured to cover the dressing assembly and to create a sealed space between the dressing assembly and the tissue site. The reduced-pressure source may be configured to be coupled in fluid communication with the sealed space.
According to another illustrative embodiment, provided is a dressing assembly that may include a dressing bolster, a comfort layer, and a sealing ring. The dressing bolster may comprise a foam and may have a first side and a second side. The comfort layer may have a first side and a second side, and the first side of the comfort layer may be coupled to the second side of the dressing bolster. The sealing ring may comprise an absorbent and may have a first side and a second side. The first side of the sealing ring may be coupled to the second side of the comfort layer and may be positioned around a circumference of the dressing bolster. At least a portion of the second side of the comfort layer may be exposed.
According to another illustrative embodiment, provided is a method for treating a tissue site that may include disposing a dressing assembly proximate to the tissue site. The dressing assembly may include a dressing bolster, a comfort layer, and a sealing ring. The comfort layer may be coupled to the dressing bolster, and the sealing ring may be coupled to the comfort layer. The method may additionally include covering the dressing assembly with a sealing member to form a sealed space between the dressing assembly and the tissue site. Further, the method may include extracting fluid from the tissue site and into the dressing assembly, and absorbing the fluid from the tissue site into the sealing ring.
Other features and advantages of the illustrative embodiments will become apparent with reference to the drawings and detailed description that follow.
In the following detailed description of the illustrative embodiments, reference is made to the accompanying drawings that form a part hereof. These embodiments are described in sufficient detail to enable those skilled in the art to practice the subject matter of this disclosure. Other embodiments may be utilized, and logical, structural, mechanical, electrical, and chemical changes may be made without departing from the scope of this disclosure. To avoid detail not necessary to enable those skilled in the art to practice the embodiments described herein, the description may omit certain information known to those skilled in the art. Therefore, the following detailed description is non-limiting, with the scope of the illustrative embodiments being defined by the appended claims.
Referring primarily to
The treatment system 100 may include a dressing assembly 112 having a dressing bolster 114, or manifold member 114. In addition, the treatment system 100 may include a sealing member 116 and a reduced-pressure subsystem 118. The treatment system 100 may also include a reduced-pressure indicator 101. While the treatment system 100 is shown in the context of a reduced-pressure dressing over an incision 104, the treatment system 100 may be used on other tissue sites, including open wounds.
The dressing bolster 114 has a first side 120 and a second, inward-facing side 122. The dressing bolster 114 may be formed from any bolster material or manifold material that provides a vacuum space, or treatment space. For example, the dressing bolster 114 may be formed from a porous and permeable foam or foam-like material, a member formed with pathways, a graft, a gauze, or any combination thereof. In some embodiments, the dressing bolster 114 may be a reticulated, open-cell polyurethane or polyether foam that may be fluid permeable. Reduced pressure applied to the dressing bolster 114 may enhance the permeability of the dressing bolster 114. One such foam material may be a VAC® GranuFoam® material available from Kinetic Concepts, Inc. (KCI) of San Antonio, Tex. The term “manifold” as used herein may refer to a substance or structure that may assist in applying reduced pressure to, delivering fluids to, or removing fluids from a tissue site. A manifold may include a plurality of flow channels or pathways. The plurality of flow channels may be interconnected to improve distribution of fluids provided to and removed from the area of tissue around the manifold. Examples of manifolds may include, without limitation, devices that have structural elements arranged to form flow channels, cellular foam, such as open-cell foam, porous tissue collections, and liquids, gels, and foams that include or cure to include flow channels.
The reticulated pores of the GranuFoam® material may be helpful in carrying out the manifold function, but as stated above, other materials may be utilized. A material with a higher or lower density than the GranuFoam® material may be desirable in some embodiments. This material may have, for example, a smaller pore size than the GranuFoam® material. Among the many possible materials, the following may be used: GranuFoam® material, FXI technical foam (www.fxi.com), gauze, a flexible channel-containing member, a graft, and other similar materials. In some embodiments, ionic silver may be added to the material, such as, for example, by a micro bonding process. Other substances, such as antimicrobial agents, may also be added to the material.
A comfort layer 124 having a first side 126 and a second, inward-facing side 128 may be coupled, for example, by a heat bond 130 or other suitable technique to the second, inward-facing side 122 of the dressing bolster 114. The comfort layer 124 may enhance patient comfort when the dressing bolster 114 is adjacent to the epidermis 106 of a patient. The comfort layer 124 may be any material that helps prevent skin irritation and discomfort while allowing fluid transmission through the comfort layer 124. As non-limiting examples, a woven material, an elastic material, a polyester knit textile substrate, a non-woven material, or a fenestrated film may be utilized. As another non-limiting example, an InterDry™ textile material from Milliken Chemical, a division of Milliken & Company, Inc. of Spartanburg, S.C., may be utilized. In some embodiments, the comfort layer 124 may include antimicrobial substances, such as silver.
The dressing bolster 114 may include a plurality of flexibility notches or recesses, analogous to notches 218 shown in
The dressing bolster 114 may have lateral edges (not shown) that are orthogonal with respect to the second, inward-facing side 122 of the dressing bolster 114. The lateral edges of the dressing bolster 114 may be analogous to lateral edges 205 of dressing bolster 204 depicted in
The sealing member 116 may provide a fluid seal over the dressing bolster 114 and at least a portion of the epidermis 106 of the patient. As such, the sealing member 116 may be formed from any material that allows for a fluid seal. “Fluid seal,” or “seal,” may be a seal adequate to maintain reduced pressure at a desired site given the particular reduced-pressure source or subsystem involved. The sealing member 116 may be sealed against the epidermis 106, or against a gasket or drape, by a sealing apparatus, such as, for example, a pressure-sensitive adhesive.
The sealing apparatus may take numerous forms, such as an adhesive sealing tape, drape tape, or strip; double-side drape tape; pressure-sensitive adhesive; paste; hydrocolloid; hydrogel; or other suitable sealing device. If a tape is used, the tape may be formed of the same material as the sealing member 116 with a pre-applied, pressure-sensitive adhesive. The pressure-sensitive adhesive may be applied on a side of the sealing member 116 adapted to face the epidermis 106, such as an inward-facing side of the sealing member 116. The pressure-sensitive adhesive may provide a fluid seal between the sealing member 116 and the epidermis, and may be utilized in combination with a gasket or drape against the epidermis 106. Before the sealing member 116 is secured to the epidermis 106, removable strips or release liners that cover the pressure-sensitive adhesive may be removed.
The sealing member 116 may be an elastomeric material or any material or substance that provides a fluid seal. “Elastomeric” may refer to a material having the properties of an elastomer, such as a polymeric material that has rubber-like properties. Some elastomers may have ultimate elongations greater than 100% and a significant amount of resilience. The resilience of a material may refer to the ability of the material to recover from an elastic deformation. Examples of elastomers may include, without limitation, natural rubbers, polyisoprene, styrene butadiene rubber, chloroprene rubber, polybutadiene, nitrile rubber, butyl rubber, ethylene propylene rubber, ethylene propylene diene monomer, chlorosulfonated polyethylene, polysulfide rubber, polyurethane, EVA film, co-polyester, and silicones. Further, sealing member materials may include a silicone drape, a 3M Tegaderm® drape, an acrylic drape, such as one available from Avery Dennison, or an incise drape.
The sealing member 116 may be comprised of a material having a high moisture vapor transmission rate (MVTR). Use of a high MVTR material for the sealing member 116 may permit moisture vapor to pass through the sealing member 116, external to the dressing assembly 112, while maintaining the fluid seal described above.
The sealing member 116 may include a first sealing member portion 132 and a second sealing member portion 134. The first sealing member portion 132 may extend over the first side 120 of the dressing bolster 114. The sealing member 116 may extend further to form a sealing member flange, or sealing member extension 136, which has a first side (not shown) and a second, inward-facing side (not shown). The second, inward-facing side of the sealing member extension 136 may be adapted to face the epidermis 106. An aperture (not shown) may be formed on a portion of the sealing member 116 to allow fluid communication with a conduit interface 138, which may be part of a reduced-pressure assembly 140. The aperture on the sealing member 116 may be analogous to aperture 234 depicted in
The second, inward-facing side of the sealing member extension 136 may be placed on a first side (not shown) of the second sealing member portion 134, and coupled, such as by an adhesive, a bond 135, a weld (e.g., ultrasonic or RF welding), or by cements. The first side of the second sealing member portion 134 may face away from the epidermis 106. In another embodiment, the first sealing member portion 132 and the second sealing member portion 134 may be integrally formed with one another. The first sealing member portion 132 may include a plurality of bellows 142, folds, or stretch zones. The bellows 142 may provide additional drape material when needed to respond to stretching or other movement. For example, if the dressing assembly 112 is used on a joint, when the joint is flexed, the bellows 142 may provide additional drape material to facilitate such movement.
Prior to application, one or more release members (not shown) may be releasably coupled to the first side of the second sealing member portion 134. The release members may be analogous to release members 242 depicted in
Release members suitable for use with the embodiments described herein may be, for example, polyester release members specified as FRA 301(T-36) and FRA 396-T13, available from Fox River Associates, LLC of Geneva, Ill. The polyester release members may be a polyethylene terephthalate (PET) release member as described below. In some embodiments, the release members may have a film thickness between about 30 microns to about 70 microns. In other embodiments, the film thickness between about 47 microns to about 53 microns. Further, the release members may have a tensile break strength in a machine direction between about 9 kilograms per square millimeter to about 15 kilograms per square millimeter. In a transverse direction, or direction transverse to the machine direction, the release members may have a tensile break strength between about 15 kilograms per square millimeter to about 23 kilograms per square millimeter. The elongation at break of the release members in both the machine direction and the transverse direction may be between about 40 percent to about 140 percent. The release members may have a shrinkage in the machine direction between about 0.0 percent to about 2.5 percent, and a shrinkage in the transverse direction between about 0.0 percent to about 1.2 percent.
The reduced-pressure subsystem 118 may include a reduced-pressure source 144. The reduced-pressure source 144 may provide reduced pressure as a part of the treatment system 100. The reduced-pressure source 144 may be fluidly coupled to the conduit interface 138 by a delivery conduit 148.
As used herein, “reduced pressure” may refer to a pressure less than the ambient pressure at a tissue site being subjected to treatment, such as the tissue site 102. The reduced pressure may be less than the atmospheric pressure. The reduced pressure may also be less than a hydrostatic pressure at a tissue site. Unless otherwise indicated, quantitative values of pressure stated herein are gauge pressures.
The reduced pressure delivered to the dressing bolster 114 may be constant or varied, patterned or random, and may be delivered continuously or intermittently. Although the terms “vacuum” and “negative pressure” may be used to describe the pressure applied to a tissue site, the actual pressure applied to the tissue site may be more than the pressure normally associated with a complete vacuum. Consistent with the use herein, unless otherwise indicated, an increase in reduced pressure or vacuum pressure may refer to a relative reduction in absolute pressure.
The reduced-pressure source 144 is shown in
The reduced-pressure source 144 may be any device for supplying a reduced pressure, such as a vacuum pump, wall suction, or other source. While the amount and nature of reduced pressure applied to a tissue site may vary according to the application, the reduced pressure may be, for example, between about −5 mm Hg (−667 Pa) to about −500 mm Hg (−66.7 kPa). In some embodiments, the reduced pressure may be between about −75 mm Hg (−9.9 kPa) to about −300 mm Hg (−39.9 kPa).
The reduced pressure developed by the reduced-pressure source 144 may be delivered through the delivery conduit 148 to the conduit interface 138. The conduit interface 138 may allow the reduced pressure to be delivered through the sealing member 116 to the dressing bolster 114. In some embodiments, the conduit interface 138 may provide fluid communication external to the sealing member 116 without the application of reduced pressure.
In providing treatment with the treatment system 100, it may be desirable to know that reduced pressure of at least a certain threshold level is being delivered to the tissue site 102. The reduced-pressure indicator 101 may indicate such a threshold pressure. The reduced-pressure indicator 101 may be a separate unit fluidly coupled to the sealing member 116 such that reduced pressure from within the sealed space of the sealing member 116 reaches the reduced-pressure indicator 101. In some embodiments, as shown in
Referring primarily to
The sealing ring 117 may be adapted to be positioned between the dressing assembly 112 and the epidermis 106 and/or the tissue site 102. The sealing ring 117 may be formed, as an illustrative example, by applying or bonding a ring of sealing material to the dressing assembly 112. The sealing material may include hydrocolloids, hydrogels, silicone polymers (both crosslinked and uncrosslinked gels), and natural gums (xanthan, guar, cellulose). The sealing material may include other soft polymer gels, such as, for example, those based on polyurethanes, polyolefin gels, and acrylics.
The sealing ring 117 may be deployed by hand or extruded from an applicator, such as a syringe, to form a ring prior to application of the dressing assembly 112 to the tissue site 102. Sealing materials suitable for application by extrusion may include water soluble gums such as xanthan, guar, or cellulose, and thick greases, such as silicones. In another embodiment, the sealing ring 117 may be bonded in any suitable manner, such as, for example, by a heat bond, to the second, inward facing side 128 of the comfort layer 124 during manufacture of the dressing assembly 112. In this manner, the sealing ring 117 may be adapted to be positioned between the comfort layer 124 and the epidermis 106 and/or the tissue site 102.
In one embodiment, the sealing ring 117 may include an absorbent. For example, the sealing ring 117 may be a hydrocolloid comprising an absorbent, such as carboxy methyl cellulose (CMC). The absorbent may permit the sealing ring 117 to absorb fluid from the tissue site 102 in addition to enhancing the fluid seal around the tissue site 102. The sealing ring 117 including the absorbent may enhance the ability of the dressing assembly 112 to manage and direct fluid away from the tissue site 102 for keeping the tissue site 102 dry. For example, the dressing bolster 114 may have a thickness between the first side 120 and the second, inward-facing side 122 of the dressing bolster 114. The thickness of the dressing bolster 114 may define at least a portion of a thickness of the dressing assembly 112. The sealing ring 117 may be adapted to be positioned between the dressing assembly 112 and the tissue site 102, as described above, and around or surrounding a circumference of the tissue site 102. Relative to the dressing assembly 112, the sealing ring 117 may be positioned, for example, around, on, or at the lateral edges of the dressing bolster 114 and/or the comfort layer 124. Further, the sealing ring 117 may be positioned around or surrounding a circumference of the dressing bolster 114 and/or the comfort layer 124. Further, the sealing ring 117 may be positioned around at least a portion of the dressing bolster 114 or the comfort layer 124 that is configured to be positioned directly against or in direct contact with the tissue site 102. At least a portion of the dressing bolster 114 and/or the comfort layer 124 may be exposed and configured to be positioned directly against the tissue site 102 when the sealing ring 117 is positioned on the dressing assembly 112. Further, in such embodiments, the sealing ring 117 may surround the exposed portion of the dressing bolster 114 and/or the comfort layer 124.
The absorbent in the sealing ring 117 may wick or draw fluid in a lateral direction within the dressing assembly 112, normal to the thickness of the dressing bolster 114, and toward the lateral edges of the dressing bolster 114 for absorption in the sealing ring 117. Thus, fluid from the tissue site 102 may be wicked or otherwise drawn in a lateral direction along the surface of the tissue site 102 toward the lateral edges of the dressing bolster 114 and into the sealing ring 117. Further, fluid from the tissue site 102 may also flow through the thickness of the dressing assembly 112 and the dressing bolster 114 at least by operation of the manifold material comprising the dressing bolster 114, described above.
Referring now primarily to
The comfort layer 210 may be any material that helps prevent skin irritation and discomfort while allowing fluid transmission through the comfort layer 210. Suitable materials for the comfort layer 210 have been mentioned in connection with the comfort layer 124 of
In some illustrative embodiments, the dressing bolster 204 may include a plurality of flexibility notches 218. The flexibility notches 218 may extend partially through or completely through the dressing bolster 204. The flexibility notches 218 may be lateral notches, or lateral cuts, in the dressing bolster 204. The flexibility notches 218 may also be one or more longitudinal notches, longitudinal cuts, or other cuts. The cuts may be made using a saw, a notched blade, a hot knife, or other device. The flexibility notches 218 may enhance the flexibility of the dressing bolster 204. The enhanced flexibility may be particularly useful when the dressing assembly 202 is applied over a joint or other area of movement on a patient. For example, if the dressing bolster 204 is used on a knee, the dressing bolster 204 may need to flex or extend as much as 100% or more. The flexibility notches 218 may provide such flexibility.
The dressing bolster 204 may have lateral edges 205 that are orthogonal with respect to the second, inward-facing side 208 of the dressing bolster 204. The lateral edges 205 may also have a shape, such as, for example, a beveled, angled, or rounded shape. The lateral edges 205, when angled, may be between about 10 degrees to about 90 degrees with respect to the second, inward-facing side 208 of the dressing bolster 204. The shaped lateral edges 205 may reduce shear stress between an epidermis of a patient and the dressing bolster 204. Other dimensions, steps, and processes may be used.
In some illustrative embodiments, the dressing bolster 204 may be manufactured from a foam block of Granufoam® material. The Granufoam® material may be, for example, a foam block having the dimensions of 1.21 meters×1.8 meters×0.5 meters. The foam block may be cut to have a 19 millimeter height, and a saw may be used to form lateral grooves, such as the flexibility notches 218, in the foam block. A dry layer, such as the comfort layer 210, may be laminated or otherwise attached to the second, inward facing side 208 of the dressing bolster 204. The foam block may be cut, for example, utilizing a die cutter to form a plurality of individual dressing bolsters 204.
A sealing subsystem 222 may provide a fluid seal over the dressing assembly 202 and at least a portion of an epidermis of a patient. The sealing subsystem 222 may include a sealing member 224. The sealing member 224 may be formed with an upper drape portion or first sealing member portion 226 and a lower drape portion or second sealing member portion 228. The first sealing member portion 226 may extend over the first side 206 of the dressing bolster 204 to form a drape flange, or drape extension 230. The drape extension 230 has a first side 232 and a second, inward-facing side 233. The second, inward-facing side 233 of the drape extension 230 may be adapted to face a tissue site of a patient as described above. An aperture 234 may be formed on the first sealing member portion 226. The aperture 234 may provide fluid communication with a conduit interface (not shown). The conduit interface may be analogous to the conduit interface 138 in
The second sealing member portion 228 may have a first side 236 and a second, inward-facing side 237 adapted to face a tissue site as described above. The second, inward-facing side 233 of the drape extension 230 may be placed on the first side 236 of the second sealing member portion 228, and may be coupled to the first side 236 by an attachment device 238. The attachment device 238 may be, for example, an adhesive, a bond, a weld (e.g., ultrasonic or RF weld), cements, stitching, staples, or other coupling device. The second sealing member portion 228 may include an attachment apparatus on the second, inward-facing side 237 as described below. The second sealing member portion 228 may also include a treatment area aperture 240, depicted in
The first sealing member portion 226 may include a plurality of folds 220 or bellows to facilitate movement as described above. The folds 220 may allow the first sealing member portion 226 to expand. For example, if the dressing assembly 202 is used on a joint, when the joint is flexed, additional drape material from the folds 220 may be released to facilitate movement of the first sealing member portion 226. The folds 220 may also be formed as ridges having the cross-sectional shape of an accordion that provides additional drape material when flattened or stretched, for example.
One or more release members 242 may be releasably coupled to the first side 236 of the second sealing member portion 228, such as, for example, with an adhesive (not shown) applied on at least a portion of the first side 236. Four of the release members 242 are shown in the illustrative embodiment of
The first side 236 of the second sealing member portion 228 may include an adhesive 244 adapted to retain the dressing bolster 204 against the second sealing member portion 228 during assembly and usage. A center release member 246 may cover and protect the adhesive 244 prior to assembly. The release members 242 that may provide stiffness to the sealing member 224 during deployment may be positioned outboard of the adhesive 244 on the first surface 236 of the second sealing member portion 228.
The dressing assembly 202 may include a sealing ring 248. Analogous to the sealing ring 117, the sealing ring 248 may help seal any wrinkles or discontinuities in the epidermis or drape that might otherwise cause leaks. The sealing ring 248 may be, for example, positioned to cover a portion of the second, inward-facing side 237 of the second sealing member portion 228. The sealing ring 248 may be coupled directly to the dressing assembly 202, or coupled with an optional sealing-ring attachment device 249, such as an acrylic adhesive, cement, or other coupling device. In other embodiments, the sealing ring 248 may be coupled to the second inward-facing side 208 of the dressing bolster 204, and/or to an adjacent layer, such as the comfort layer 210.
The sealing ring 248 may straddle an edge of the dressing bolster 204, or otherwise extend beyond an edge of the dressing bolster 204, as depicted in
The sealing ring 248 may comprise a sealing material, such as, for example, any of the sealing materials previously described in connection with the sealing ring 117, or other material that provides initial tack between the dressing assembly 202 and an epidermis of a patient. Further, the sealing ring 248 may have a durometer, such as a material softness or hardness, between about 20 Shore 00 to about 90 Shore OO. In some embodiments, the durometer of the sealing ring 248 may be between about 70 Shore 00 to about 80 Shore OO. The sealing ring 248 may have a modulus of elasticity that falls between the modulus of elasticity of the second sealing member portion 228 and the modulus of elasticity of a tissue site and/or epidermis of a patient. As shown in
In some embodiments, the second sealing member portion 228 may have a thickness 229 between about 0.178 millimeters to about 0.254 millimeters, or about 7 mils to about 10 mils. The ratio of the sealing ring thickness 250 to the sealing member thickness 229 may be between about 2.75 to about 7.03.
The sealing ring 248 may include fenestrations or apertures. In some embodiments, the sealing ring 248 may comprise a patterned sealing material on the second, inward-facing side 214 of the comfort layer 210, or on the second, inward-facing side 208 of the dressing bolster 204. The pattern may be, for example, spaced islands, crossing lines of sealing material, or any other suitable pattern.
The sealing ring 248 may function as a two-sided gasket that may provide a seal between the dressing assembly 202 and a tissue site and/or epidermis of a patient. For example, the sealing ring 248 may provide a seal between the dressing bolster 204, the comfort layer 210, or the second sealing member portion 228 and a tissue site and/or epidermis of a patient. The sealing ring 248 may absorb perspiration or other fluids from a tissue site. Further, the sealing ring 248 may help distribute shear forces created, for example, by the application of reduced pressure at the interface of the dressing bolster 204 and a tissue site and/or epidermis of a patient.
As shown in
The bottom release member 256 may cover and protect, for example, the sealing device 254 and the sealing ring 248. The side release members 258 may also cover and protect the sealing device 254. Similar to the release members 242, the side release members 258 may provide a grasping surface for a user to facilitate deployment of the dressing assembly 202. The release members 242, the bottom release member 256, and/or the side release members 258 may be comprised of a polar semi-crystalline polymer, such as, for example, polyethylene terephthalate (PET). Use of a polar semi-crystalline polymer for the release members 242, the bottom release member 256, and/or the side release members 258 may substantially preclude wrinkling or other deformation of the dressing assembly 202. Any deformation of the release members 242, the bottom release member 256, and/or the side release members 258 may cause wrinkling or deformation of a component of the dressing assembly 202. The polar semi-crystalline polymer is highly orientated and resistant to softening, swelling, or other deformation that may occur when brought into contact with components of the dressing assembly 202, or when subjected to temperature or environmental variations, or sterilization. Thus, for example, when the polar semi-crystalline polymer is used in combination with the hydrocolloid described above for the sealing ring 248, the polar semi-crystalline polymer may not deform when in contact with the compounding ingredients of the hydrocolloid. In some embodiments, the release members 242, the bottom release member 256, and/or the side release members 258 may be configured to resist deformation when exposed to temperature variations between about 40 degrees Celsius to about 60 degrees Celsius, and gamma sterilization doses between about 25 kGy to about 45 kGy.
Continuing with
Regarding the manufacture of the systems and components described above, in applying and coupling a sealing member to a dressing bolster, a press may be utilized to remove any wrinkles in the sealing member. Further, the medical bolster material of the shaped dressing assembly may be cut using a die cutter, or by hand with a router.
Referring now primarily to
Referring now to
The dressing assembly 314 may include a comfort layer 326. The second, inward-facing side 324 of the dressing bolster 316 may be covered with the comfort layer 326. The comfort layer 326 has first side 328 and a second, inward-facing side 330. The first side 328 of the comfort layer 326 may be coupled by an attachment device 332, such as, for example, a heat bond, adhesive, weld, or other attachment device, to the second, inward-facing side 324 of the dressing bolster 316.
The dressing assembly 314 may include a sealing ring 334. The sealing ring 334 may be coupled, at least in part, to the second, inward-facing side 330 of the comfort layer 326. The sealing ring 334 may be analogous to the sealing ring 117 of
Prior to application, a second, inward-facing surface 338 of the sealing ring 334 may be covered by a release member or release liner (not shown). When the release liner is removed, the sealing ring 334 may be centered about the linear wound 306 for deployment. A release member or release liner (not shown) may also temporarily cover a portion of the sealing ring 334 and/or sealing ring attachment device 336 to provide a grasping surface during deployment of the dressing assembly 314. The release liner or release member covering, for example, the sealing ring 334, the sealing ring attachment device 336, and/or other components of the dressing assembly 314 may be analogous to the release members 242, 256, and 258 of
Referring now to
The dressing assembly 314 may be cut to accommodate different sizes of linear wounds 306 prior to being disposed on the linear wound 306 and covered with the sealing member 340. As shown in
A first longitudinal end 352 of a third dressing assembly 354 may be placed proximate to and abutting a lateral end or edge 356 of the second dressing assembly 350. Once the combination of dressing assemblies is arranged, the dressing assemblies 346, 350, 354 may be covered with a sealing member (not shown but analogous to sealing member 340 in
Referring now primarily to
A comfort layer 412 may be coupled by an attachment device 414 to the second, inward-facing side 406 of the dressing bolster 402. A sealing ring 416 may be coupled to the comfort layer 412. The sealing ring 416 may be formed from the sealing materials previously mentioned. The sealing ring 416 may be coupled directly to the comfort layer 412, or may be attached to the comfort layer 412 by an attachment device, such as an acrylic adhesive (not shown).
Analogous to the previously described embodiments, in operation, the dressing assembly 400 may be placed over and about a linear wound and then covered with a sealing member to form a sealed space. Reduced pressure may then be delivered to the sealed space to treat the linear wound.
Referring now primarily to
In another embodiment (not explicitly shown), an attachment device, such as an adhesive, may be applied to the second, inward-facing side of a sealing ring to provide tackiness or enhanced tackiness between the sealing ring and an epidermis of a patient. The attachment device may be particularly beneficial when the sealing ring comprises a harder hydrocolloid than those previously mentioned, or when applied in cold conditions to provide time for the sealing material to warm up and become adequately tacky.
Although the subject matter of this disclosure has been provided by way of example in the context of certain illustrative, non-limiting embodiments, various changes, substitutions, permutations, and alterations can be made without departing from the scope of this disclosure as defined by the appended claims. Any feature described in connection to any one embodiment may also be applicable to any other embodiment. As such, the benefits and advantages described above may relate to one embodiment or may relate to several embodiments. Further, the steps of the methods described herein may be carried out in any suitable order, or simultaneously where appropriate.
This application claims the benefit, under 35 USC § 119(e), of the filing of U.S. Provisional Patent Application Ser. No. 61/870,080, entitled “DRESSING INTERFACE WITH MOISTURE CONTROLLING FEATURE AND SEALING FUNCTION,” filed Aug. 26, 2013, which is incorporated herein by reference for all purposes.
| Number | Name | Date | Kind |
|---|---|---|---|
| 1355846 | Rannells | Oct 1920 | A |
| 2547758 | Keeling | Apr 1951 | A |
| 2632443 | Lesher | Mar 1953 | A |
| 2682873 | Evans et al. | Jul 1954 | A |
| 2910763 | Lauterbach | Nov 1959 | A |
| 2969057 | Simmons | Jan 1961 | A |
| 3066672 | Crosby, Jr. et al. | Dec 1962 | A |
| 3172808 | Baumann et al. | Mar 1965 | A |
| 3367332 | Groves | Feb 1968 | A |
| 3376868 | Mondiadis | Apr 1968 | A |
| 3520300 | Flower, Jr. | Jul 1970 | A |
| 3568675 | Harvey | Mar 1971 | A |
| 3648692 | Wheeler | Mar 1972 | A |
| 3682180 | McFarlane | Aug 1972 | A |
| 3742952 | Magers et al. | Jul 1973 | A |
| 3774611 | Tussey et al. | Nov 1973 | A |
| 3777016 | Gilbert | Dec 1973 | A |
| 3779243 | Tussey et al. | Dec 1973 | A |
| 3826254 | Mellor | Jul 1974 | A |
| 3852823 | Jones | Dec 1974 | A |
| 3967624 | Milnamow | Jul 1976 | A |
| 3983297 | Ono et al. | Sep 1976 | A |
| 4080970 | Miller | Mar 1978 | A |
| 4096853 | Weigand | Jun 1978 | A |
| 4139004 | Gonzalez, Jr. | Feb 1979 | A |
| 4141361 | Snyder | Feb 1979 | A |
| 4163822 | Walter | Aug 1979 | A |
| 4165748 | Johnson | Aug 1979 | A |
| 4184510 | Murry et al. | Jan 1980 | A |
| 4233969 | Lock et al. | Nov 1980 | A |
| 4245630 | Lloyd et al. | Jan 1981 | A |
| 4256109 | Nichols | Mar 1981 | A |
| 4261363 | Russo | Apr 1981 | A |
| 4275721 | Olson | Jun 1981 | A |
| 4284079 | Adair | Aug 1981 | A |
| 4297995 | Golub | Nov 1981 | A |
| 4333468 | Geist | Jun 1982 | A |
| 4360015 | Mayer | Nov 1982 | A |
| 4373519 | Errede et al. | Feb 1983 | A |
| 4382441 | Svedman | May 1983 | A |
| 4392853 | Muto | Jul 1983 | A |
| 4392858 | George et al. | Jul 1983 | A |
| 4414970 | Berry | Nov 1983 | A |
| 4419097 | Rowland | Dec 1983 | A |
| 4465485 | Kashmer et al. | Aug 1984 | A |
| 4475909 | Eisenberg | Oct 1984 | A |
| 4480638 | Schmid | Nov 1984 | A |
| 4525166 | Leclerc | Jun 1985 | A |
| 4525374 | Vaillancourt | Jun 1985 | A |
| 4529402 | Weilbacher et al. | Jul 1985 | A |
| 4540412 | Van Overloop | Sep 1985 | A |
| 4543100 | Brodsky | Sep 1985 | A |
| 4548202 | Duncan | Oct 1985 | A |
| 4551139 | Plaas et al. | Nov 1985 | A |
| 4569348 | Hasslinger | Feb 1986 | A |
| 4605399 | Weston et al. | Aug 1986 | A |
| 4608041 | Nielson | Aug 1986 | A |
| 4640688 | Hauser | Feb 1987 | A |
| 4655754 | Richmond et al. | Apr 1987 | A |
| 4664652 | Weilbacher | May 1987 | A |
| 4664662 | Webster | May 1987 | A |
| 4710165 | McNeil et al. | Dec 1987 | A |
| 4715857 | Juhasz et al. | Dec 1987 | A |
| 4733659 | Edenbaum et al. | Mar 1988 | A |
| 4743232 | Kruger | May 1988 | A |
| 4753230 | Carus et al. | Jun 1988 | A |
| 4758220 | Sundblom et al. | Jul 1988 | A |
| 4787888 | Fox | Nov 1988 | A |
| 4826494 | Richmond et al. | May 1989 | A |
| 4832008 | Gilman | May 1989 | A |
| 4838883 | Matsuura | Jun 1989 | A |
| 4840187 | Brazier | Jun 1989 | A |
| 4848364 | Bosman | Jul 1989 | A |
| 4863449 | Therriault et al. | Sep 1989 | A |
| 4871611 | LeBel | Oct 1989 | A |
| 4872450 | Austad | Oct 1989 | A |
| 4878901 | Sachse | Nov 1989 | A |
| 4897081 | Poirier et al. | Jan 1990 | A |
| 4906233 | Moriuchi et al. | Mar 1990 | A |
| 4906240 | Reed et al. | Mar 1990 | A |
| 4919654 | Kalt et al. | Apr 1990 | A |
| 4930997 | Bennett | Jun 1990 | A |
| 4941882 | Ward et al. | Jul 1990 | A |
| 4953565 | Tachibana et al. | Sep 1990 | A |
| 4961493 | Kaihatsu | Oct 1990 | A |
| 4969880 | Zamierowski | Nov 1990 | A |
| 4981474 | Bopp et al. | Jan 1991 | A |
| 4985019 | Michelson | Jan 1991 | A |
| 4995382 | Lang et al. | Feb 1991 | A |
| 4996128 | Aldecoa et al. | Feb 1991 | A |
| 5010883 | Rawlings et al. | Apr 1991 | A |
| 5018515 | Gilman | May 1991 | A |
| 5037397 | Kalt et al. | Aug 1991 | A |
| 5086170 | Luheshi et al. | Feb 1992 | A |
| 5092323 | Riedel et al. | Mar 1992 | A |
| 5092858 | Benson et al. | Mar 1992 | A |
| 5100396 | Zamierowski | Mar 1992 | A |
| 5112323 | Winkler et al. | May 1992 | A |
| 5134994 | Say | Aug 1992 | A |
| 5149331 | Ferdman et al. | Sep 1992 | A |
| 5151314 | Brown | Sep 1992 | A |
| 5152757 | Eriksson | Oct 1992 | A |
| 5167613 | Karami et al. | Dec 1992 | A |
| 5176663 | Svedman et al. | Jan 1993 | A |
| 5180375 | Feibus | Jan 1993 | A |
| 5215522 | Page et al. | Jun 1993 | A |
| 5232453 | Plass et al. | Aug 1993 | A |
| 5261893 | Zamierowski | Nov 1993 | A |
| 5266372 | Arakawa et al. | Nov 1993 | A |
| 5270358 | Asmus | Dec 1993 | A |
| 5278100 | Doan et al. | Jan 1994 | A |
| 5279550 | Habib et al. | Jan 1994 | A |
| 5298015 | Komatsuzaki et al. | Mar 1994 | A |
| 5342329 | Croquevielle | Aug 1994 | A |
| 5342376 | Ruff | Aug 1994 | A |
| 5344415 | DeBusk et al. | Sep 1994 | A |
| 5356386 | Goldberg et al. | Oct 1994 | A |
| 5358494 | Svedman | Oct 1994 | A |
| 5384174 | Ward et al. | Jan 1995 | A |
| 5387207 | Dyer et al. | Feb 1995 | A |
| 5419769 | Devlin et al. | May 1995 | A |
| 5423778 | Eriksson et al. | Jun 1995 | A |
| 5429590 | Saito et al. | Jul 1995 | A |
| 5437622 | Carion | Aug 1995 | A |
| 5437651 | Todd et al. | Aug 1995 | A |
| 5445604 | Lang | Aug 1995 | A |
| 5447492 | Cartmell et al. | Sep 1995 | A |
| 5522808 | Skalla | Jun 1996 | A |
| 5527293 | Zamierowski | Jun 1996 | A |
| 5549584 | Gross | Aug 1996 | A |
| 5549585 | Maher et al. | Aug 1996 | A |
| 5556375 | Ewall | Sep 1996 | A |
| 5585178 | Calhoun et al. | Dec 1996 | A |
| 5599292 | Yoon | Feb 1997 | A |
| 5607388 | Ewall | Mar 1997 | A |
| 5634893 | Rishton | Jun 1997 | A |
| 5636643 | Argenta et al. | Jun 1997 | A |
| 5641506 | Talke et al. | Jun 1997 | A |
| 5645081 | Argenta et al. | Jul 1997 | A |
| 5653224 | Johnson | Aug 1997 | A |
| 5678564 | Lawrence et al. | Oct 1997 | A |
| 5710233 | Meckel et al. | Jan 1998 | A |
| 5714225 | Hansen et al. | Feb 1998 | A |
| 5736470 | Schneberger et al. | Apr 1998 | A |
| 5776119 | Bilbo et al. | Jul 1998 | A |
| 5807295 | Hutcheon et al. | Sep 1998 | A |
| 5919476 | Fischer et al. | Jul 1999 | A |
| 5941863 | Guidotti et al. | Aug 1999 | A |
| 6071267 | Zamierowski | Jun 2000 | A |
| 6086995 | Smith | Jul 2000 | A |
| 6135116 | Vogel et al. | Oct 2000 | A |
| 6174306 | Fleischmann | Jan 2001 | B1 |
| 6191335 | Robinson | Feb 2001 | B1 |
| 6241747 | Ruff | Jun 2001 | B1 |
| 6262329 | Brunsveld et al. | Jul 2001 | B1 |
| 6287316 | Agarwal et al. | Sep 2001 | B1 |
| 6345623 | Heaton et al. | Feb 2002 | B1 |
| 6458109 | Henley et al. | Oct 2002 | B1 |
| 6488643 | Tumey et al. | Dec 2002 | B1 |
| 6493568 | Bell et al. | Dec 2002 | B1 |
| 6495229 | Carte et al. | Dec 2002 | B1 |
| 6548727 | Swenson | Apr 2003 | B1 |
| 6553998 | Heaton et al. | Apr 2003 | B2 |
| 6566575 | Stickels et al. | May 2003 | B1 |
| 6566577 | Addison et al. | May 2003 | B1 |
| 6626891 | Ohmstede | Sep 2003 | B2 |
| 6648862 | Watson | Nov 2003 | B2 |
| 6680113 | Lucast et al. | Jan 2004 | B1 |
| 6685681 | Lockwood et al. | Feb 2004 | B2 |
| 6693180 | Lee et al. | Feb 2004 | B2 |
| 6695823 | Lina et al. | Feb 2004 | B1 |
| 6752794 | Lockwood et al. | Jun 2004 | B2 |
| 6787682 | Gilman | Sep 2004 | B2 |
| 6814079 | Heaton et al. | Nov 2004 | B2 |
| 6855135 | Lockwood et al. | Feb 2005 | B2 |
| 6856821 | Johnson | Feb 2005 | B2 |
| 6979324 | Bybordi et al. | Dec 2005 | B2 |
| 7070584 | Johnson et al. | Jul 2006 | B2 |
| 7154017 | Sigurjonsson et al. | Dec 2006 | B2 |
| 7569742 | Haggstrom et al. | Aug 2009 | B2 |
| 7645269 | Zamierowski | Jan 2010 | B2 |
| 8298197 | Eriksson et al. | Oct 2012 | B2 |
| 8632523 | Eriksson et al. | Jan 2014 | B2 |
| 8764732 | Hartwell | Jul 2014 | B2 |
| 9192444 | Locke et al. | Nov 2015 | B2 |
| 20010030304 | Kohda et al. | Oct 2001 | A1 |
| 20010051178 | Blatchford et al. | Dec 2001 | A1 |
| 20020009568 | Bries et al. | Jan 2002 | A1 |
| 20020016346 | Brandt et al. | Feb 2002 | A1 |
| 20020065494 | Lockwood et al. | May 2002 | A1 |
| 20020077661 | Saadat | Jun 2002 | A1 |
| 20020115951 | Norstrem et al. | Aug 2002 | A1 |
| 20020119292 | Venkatasanthanam et al. | Aug 2002 | A1 |
| 20020120185 | Johnson | Aug 2002 | A1 |
| 20020130064 | Adams et al. | Sep 2002 | A1 |
| 20020143286 | Tumey | Oct 2002 | A1 |
| 20020150270 | Werner | Oct 2002 | A1 |
| 20020150720 | Howard et al. | Oct 2002 | A1 |
| 20020161346 | Lockwood et al. | Oct 2002 | A1 |
| 20020164346 | Nicolette | Nov 2002 | A1 |
| 20020183702 | Henley et al. | Dec 2002 | A1 |
| 20020198504 | Risk et al. | Dec 2002 | A1 |
| 20030014022 | Lockwood et al. | Jan 2003 | A1 |
| 20030109855 | Solem et al. | Jun 2003 | A1 |
| 20030158577 | Ginn et al. | Aug 2003 | A1 |
| 20030212357 | Pace | Nov 2003 | A1 |
| 20030225347 | Argenta et al. | Dec 2003 | A1 |
| 20030225355 | Butler | Dec 2003 | A1 |
| 20040002676 | Siegwart et al. | Jan 2004 | A1 |
| 20040030304 | Hunt et al. | Feb 2004 | A1 |
| 20040064132 | Boehringer et al. | Apr 2004 | A1 |
| 20040077984 | Worthley | Apr 2004 | A1 |
| 20040127836 | Sigurjonsson et al. | Jul 2004 | A1 |
| 20040127862 | Bubb et al. | Jul 2004 | A1 |
| 20040133143 | Burton et al. | Jul 2004 | A1 |
| 20040186239 | Qin et al. | Sep 2004 | A1 |
| 20040219337 | Langley et al. | Nov 2004 | A1 |
| 20040230179 | Shehada | Nov 2004 | A1 |
| 20050034731 | Rousseau et al. | Feb 2005 | A1 |
| 20050054998 | Poccia et al. | Mar 2005 | A1 |
| 20050065484 | Watson | Mar 2005 | A1 |
| 20050070858 | Lockwood et al. | Mar 2005 | A1 |
| 20050101940 | Radl et al. | May 2005 | A1 |
| 20050113732 | Lawry | May 2005 | A1 |
| 20050131327 | Lockwood et al. | Jun 2005 | A1 |
| 20050137539 | Biggie et al. | Jun 2005 | A1 |
| 20050143694 | Schmidt et al. | Jun 2005 | A1 |
| 20050159695 | Cullen et al. | Jul 2005 | A1 |
| 20050163978 | Strobech et al. | Jul 2005 | A1 |
| 20050233072 | Stephan et al. | Oct 2005 | A1 |
| 20050256437 | Silcock et al. | Nov 2005 | A1 |
| 20050261642 | Weston | Nov 2005 | A1 |
| 20050261643 | Bybordi et al. | Nov 2005 | A1 |
| 20050277860 | Jensen | Dec 2005 | A1 |
| 20060079852 | Bubb et al. | Apr 2006 | A1 |
| 20060154546 | Murphy et al. | Jul 2006 | A1 |
| 20060241542 | Gudnason et al. | Oct 2006 | A1 |
| 20060271020 | Huang et al. | Nov 2006 | A1 |
| 20070027414 | Hoffman et al. | Feb 2007 | A1 |
| 20070078366 | Haggstrom et al. | Apr 2007 | A1 |
| 20070185426 | Ambrosio et al. | Aug 2007 | A1 |
| 20070225663 | Watt et al. | Sep 2007 | A1 |
| 20070265585 | Joshi et al. | Nov 2007 | A1 |
| 20070265586 | Joshi et al. | Nov 2007 | A1 |
| 20080090085 | Kawate et al. | Apr 2008 | A1 |
| 20080119802 | Riesinger | May 2008 | A1 |
| 20080149104 | Eifler | Jun 2008 | A1 |
| 20080195017 | Robinson et al. | Aug 2008 | A1 |
| 20080225663 | Smith et al. | Sep 2008 | A1 |
| 20080243044 | Hunt et al. | Oct 2008 | A1 |
| 20080269657 | Brenneman | Oct 2008 | A1 |
| 20080271804 | Biggie et al. | Nov 2008 | A1 |
| 20090088719 | Driskell | Apr 2009 | A1 |
| 20090124988 | Coulthard | May 2009 | A1 |
| 20090227969 | Jaeb et al. | Sep 2009 | A1 |
| 20090264807 | Haggstrom et al. | Oct 2009 | A1 |
| 20090326488 | Budig et al. | Dec 2009 | A1 |
| 20100063467 | Addison et al. | Mar 2010 | A1 |
| 20100125259 | Olson | May 2010 | A1 |
| 20100159192 | Cotton | Jun 2010 | A1 |
| 20100185163 | Heagle | Jul 2010 | A1 |
| 20100267302 | Kantner et al. | Oct 2010 | A1 |
| 20100305490 | Coulthard et al. | Dec 2010 | A1 |
| 20100324516 | Braga et al. | Dec 2010 | A1 |
| 20110160686 | Ueda et al. | Jun 2011 | A1 |
| 20110171480 | Mori et al. | Jul 2011 | A1 |
| 20110172617 | Riesinger | Jul 2011 | A1 |
| 20110224631 | Simmons et al. | Sep 2011 | A1 |
| 20110244010 | Doshi | Oct 2011 | A1 |
| 20110257617 | Franklin | Oct 2011 | A1 |
| 20120143157 | Reisinger | Jun 2012 | A1 |
| 20120209226 | Simmons | Aug 2012 | A1 |
| 20120258271 | Maughan | Oct 2012 | A1 |
| 20130030394 | Locke et al. | Jan 2013 | A1 |
| 20130066285 | Locke et al. | Mar 2013 | A1 |
| 20130096518 | Hall et al. | Apr 2013 | A1 |
| 20130152945 | Locke et al. | Jun 2013 | A1 |
| 20140039424 | Locke | Feb 2014 | A1 |
| Number | Date | Country |
|---|---|---|
| 550575 | Mar 1986 | AU |
| 745271 | Apr 1999 | AU |
| 755496 | Feb 2002 | AU |
| 2005436 | Jun 1990 | CA |
| 87101823 | Aug 1988 | CN |
| 26 40 413 | Mar 1978 | DE |
| 43 06 478 | Sep 1994 | DE |
| 295 04 378 | Oct 1995 | DE |
| 202004018245 | Jul 2005 | DE |
| 0097517 | Jan 1984 | EP |
| 0100148 | Feb 1984 | EP |
| 0117632 | Sep 1984 | EP |
| 0161865 | Nov 1985 | EP |
| 0251810 | Jan 1988 | EP |
| 0275353 | Jul 1988 | EP |
| 0358302 | Mar 1990 | EP |
| 0538917 | Apr 1993 | EP |
| 0630629 | Dec 1994 | EP |
| 0659390 | Jun 1995 | EP |
| 0633758 | Oct 1996 | EP |
| 1002846 | May 2000 | EP |
| 1018967 | Aug 2004 | EP |
| 2578193 | Apr 2013 | EP |
| 692578 | Jun 1953 | GB |
| 1386800 | Mar 1975 | GB |
| 2 195 255 | Apr 1988 | GB |
| 2 197 789 | Jun 1988 | GB |
| 2 220 357 | Jan 1990 | GB |
| 2 235 877 | Mar 1991 | GB |
| 2 329 127 | Mar 1999 | GB |
| 2 333 965 | Aug 1999 | GB |
| 2377939 | Jan 2003 | GB |
| 2392836 | Mar 2004 | GB |
| 2393655 | Apr 2004 | GB |
| 2425487 | Nov 2006 | GB |
| 2452720 | Mar 2009 | GB |
| 4129536 | Apr 1992 | JP |
| 2008080137 | Apr 2008 | JP |
| 71559 | Apr 2002 | SG |
| 8002182 | Oct 1980 | WO |
| 8704626 | Aug 1987 | WO |
| 8707164 | Dec 1987 | WO |
| 90010424 | Sep 1990 | WO |
| 9309727 | May 1993 | WO |
| 94020041 | Sep 1994 | WO |
| 9605873 | Feb 1996 | WO |
| 9622753 | Aug 1996 | WO |
| 9718007 | May 1997 | WO |
| 9913793 | Mar 1999 | WO |
| 9965542 | Dec 1999 | WO |
| 0136188 | May 2001 | WO |
| 0160296 | Aug 2001 | WO |
| 0243743 | Jun 2002 | WO |
| 02062403 | Aug 2002 | WO |
| 03-018098 | Mar 2003 | WO |
| 03045294 | Jun 2003 | WO |
| 03045492 | Jun 2003 | WO |
| 03053484 | Jul 2003 | WO |
| 2004024197 | Mar 2004 | WO |
| 2004037334 | May 2004 | WO |
| 2004112852 | Dec 2004 | WO |
| 2005002483 | Jan 2005 | WO |
| 2005062896 | Jul 2005 | WO |
| 2005105176 | Nov 2005 | WO |
| 2007022097 | Feb 2007 | WO |
| 2007030601 | Mar 2007 | WO |
| 2007070269 | Jun 2007 | WO |
| 2007085396 | Aug 2007 | WO |
| 2007087811 | Aug 2007 | WO |
| 2007113597 | Oct 2007 | WO |
| 2007133618 | Nov 2007 | WO |
| 2008041926 | Apr 2008 | WO |
| 2008054312 | May 2008 | WO |
| 2008082444 | Jul 2008 | WO |
| 2008100440 | Aug 2008 | WO |
| 2008104609 | Sep 2008 | WO |
| 2008131895 | Nov 2008 | WO |
| 2009002260 | Dec 2008 | WO |
| 2009066105 | May 2009 | WO |
| 2009066106 | May 2009 | WO |
| 2009081134 | Jul 2009 | WO |
| 2009089016 | Jul 2009 | WO |
| 2009124100 | Oct 2009 | WO |
| 2010032728 | Mar 2010 | WO |
| 2010056977 | May 2010 | WO |
| 2010129299 | Nov 2010 | WO |
| 2011008497 | Jan 2011 | WO |
| 2011043786 | Apr 2011 | WO |
| 2011049562 | Apr 2011 | WO |
| 2011115908 | Sep 2011 | WO |
| 2011121127 | Oct 2011 | WO |
| 2012104584 | Aug 2012 | WO |
| 2012112204 | Aug 2012 | WO |
| 2012140378 | Oct 2012 | WO |
| 2012143665 | Oct 2012 | WO |
| 2013009239 | Jan 2013 | WO |
| 2013090810 | Jun 2013 | WO |
| 2014113253 | Jul 2014 | WO |
| 2014140608 | Sep 2014 | WO |
| 2014143488 | Sep 2014 | WO |
| 2015065615 | May 2015 | WO |
| 2015130471 | Sep 2015 | WO |
| Entry |
|---|
| International Search Report and Written Opinion for PCT/US2014/056508 dated Dec. 9, 2014. |
| M.J. Morykwas, L.C. Argenta, E.I. Shelton-Brown, and W. McGuirt, “Vacuum-Assisted Closure: A New Method for Wound Control and Treatment: Animal Studies and Basic Foundation,” Annals of Plastic Surgery 38 (1997), pp. 553-562 (Morykwas I). |
| International Search Report and Written Opinion for PCT/GB2008/003075 dated Mar. 11, 2010. |
| International Search Report and Written Opinion for PCT/GB2008/004216 dated Jul. 2, 2009. |
| International Search Report and Written Opinion for PCT/GB2012/000099 dated May 2, 2012. |
| EP Examination Report for corresponding application 12705381.7, dated May 22, 2014. |
| International Search Report and Written Opinion for PCT/US2012/069893 dated Apr. 8, 2013. |
| International Search Report and Written Opinion for PCT/US2013/070070 dated Jan. 29, 2014. |
| International Search Report and Written Opinion for PCT/US2014/016320 dated Apr. 15, 2014. |
| International Search Report and Written Opinion for PCT/US2014/056566 dated Dec. 5, 2014. |
| International Search Report and Written Opinion for PCT/US2014/056524 dated Dec. 11, 2014. |
| International Search Report and Written Opinion for PCT/US2014/056594 dated Dec. 2, 2014. |
| Partial Internationl Search Report date dated Jul. 31, 2009; PCT Internationl Application No. PCT/US2009/036222. |
| International Search Report and Written opinion dated Dec. 15, 2009; PCT Internation Application No. PCT/US2009/036222. |
| International Search Report and Written Opinion dated Feb. 24, 2010; PCT/US2009/057182. |
| International Search Report and Written Opinion dated Jan. 5, 2010; PCT International Application No. PCT/US2009/057130. |
| Response filed Oct. 20, 2011 for U.S. Appl. No. 12/398,904. |
| Interview Summary dated Oct. 27, 2011 for U.S. Appl. No. 12/398,904. |
| Non-Final Office Action dated Jul. 20, 2011 for U.S. Appl. No. 12/398,904. |
| NDP 1000 Negative Pressure Wound Terapy System, Kalypto Medical, pp. 1-4. |
| Partial International Search Report dated Jul. 31, 2009 for PCT International Application No. PCT/US2009/036217. |
| International Search Report and Written Opinion dated May 31, 2010 for PCT Application No. PCT/US2009/064364. |
| Examination report for AU2009221772 dated Apr. 4, 2011. |
| Response filed Oct. 21, 2011 for U.S. Appl. No. 12/398,891. |
| Interview Summary dated Oct. 27, 2011 for U.S. Appl. No. 12/398,891. |
| Restriction Requirement dated Jun. 13, 2011 for U.S. Appl. No. 12/398,891. |
| Response filed Jun. 24, 2011 for U.S. Appl. No. 12/398,891. |
| Non-Final Office Action dated Jul. 21, 2011 for U.S. Appl. No. 12/398,891. |
| International Search Report and Written Opinion dated Oct. 19, 2010; PCT International Application No. PCT/US2009/036217. |
| International Search Report and Written Opinion dated Feb. 24, 2010; PCT International Application No. PCT/US2009/057182. |
| NPD 1000 Negative Pressure Would Therapy System, Kalypto Medical, pp. 1-4. |
| Partial International Search Report dated Jul. 31, 2009; PCT Internationl Application No. PCT/US2009/036222. |
| Non-Final Rejection for U.S. Appl. No. 12/398,904 dated Mar. 14, 2012. |
| Response to Non-Final Rejection for U.S. Appl. No. 12/398,904, filed Jun. 4, 2012. |
| International Search Report and Written Opinion for PCT/US2014/061251 dated May 8, 2015. |
| International Search Report and Written Opinion for PCT/IB2013/060862 dated Jun. 26, 2014. |
| International Search Report and Written Opinion for PCT/US2015/015493 dated May 4, 2015. |
| European Search Report for corresponding Application No. 15194949.2. |
| European Search Report for corresponding EPSN 15157408.4 published on Sep. 30, 2015. |
| International Search Report and Written Opinion for PCT/US2015/029037 dated Sep. 4, 2015. |
| International Search Report and Written Opinion for PCT/US2015/034289 dated Aug. 21, 2015. |
| International Search Report and Written Opinion for PCT/US2015/065135 dated Apr. 4, 2016. |
| International Search Report and Written Opinion for PCT/GB2012/050822 dated Aug. 8, 2012. |
| International Search Report and Written Opinion dated Jun. 1, 2011 for PCT International Application No. PCT/US2011/028344. |
| European Search Report for EP 11714148.1, dated May 2, 2014. |
| European Search Report for corresponding Application No. 15192606.0 dated Feb. 24, 2016. |
| European Examination Report dated Jun. 29, 2016, corresponding to EP Application No. 16173614.5. |
| International Search Report and Written Opinion for corresponding PCT/US2014/010704 dated Mar. 25, 2014. |
| International Search Report and Written Opinion for corresponding PCT/US2014/048081 dated Nov. 14, 2014. |
| N.A. Bagautdinov, “Variant of External Vacuum Aspiration in the Treatment of Purulent Diseases of the Soft Tissues,” Current Problems in Modern Clinical Surgery: Interdepartmental Collection, edited by V. Ye Volkov et al. (Chuvashia State University, Cheboksary, U.S.S.R. 1986);pp. 94-96 (copy and certified translation). |
| Louis C. Argenta, MD and Michael J. Morykwas, PhD; “Vacuum-Assisted Closure: A New Method for Wound Control and Treatment: Animal Studies & Basic Foundation”; Annals of Plastic Surgery, vol. 38, No. 6, Jun. 1997; pp. 553-562. |
| Susan Mendez-Eastmen, RN; “When Wounds Won't Heal” RN Jan. 1998, vol. 61 (1); Medical Economics Company, Inc., Montvale, NJ, USA; pp. 20-24. |
| James H. Blackburn, II, MD, et al; “Negative-Pressure Dressings as a Bolster for Skin Grafts”; Annals of Plastic Surgery, vol. 40, No. 5, May 1998, pp. 453-457. |
| John Masters; “Reliable, Inexpensive and Simple Suction Dressings”; Letters to the Editor, British Journal of Plastic Surgery, 1998, vol. 51 (3), p. 267; Elsevier Science/The British Association of Plastic Surgeons, UK. |
| S.E. Greer, et al “The Use of Subatmospheric Pressure Dressing Therapy to Close Lymphocutaneous Fistulas of the Groin” British Journal of Plastic Surgery (2000), vol. 53, pp. 484-487. |
| George V. Letsou, MD., et al; “Stimulation of Adenylate Cyclase Activity in Cultured Endothelial Cells Subjected to Cyclic Stretch”; Journal of Cardiovascular Surgery, vol. 31, 1990, pp. 634-639. |
| Orringer, Jay, et al; “Management of Wounds in Patients with Complex Enterocutaneous Fistulas”; Surgery, Gynecology & Obstetrics, Jul. 1987, vol. 165, pp. 79-80. |
| International Search Report for PCT International Application PCT/GB95/01983; dated Nov. 23, 1995. |
| PCT International Search Report for PCT International Application PCT/GB98/02713; dated Jan. 8, 1999. |
| PCT Written Opinion; PCT International Application PCT/GB98/02713; dated Jun. 8, 1999. |
| PCT International Examination and Search Report, PCT International Application PCT/GB96/02802; dated Jan. 15, 1998 & Apr. 29, 1997. |
| PCT Written Opinion, PCT International Application PCT/GB96/02802; dated Sep. 3, 1997. |
| Dattilo, Philip P., Jr., et al; “Medical Textiles: Application of an Absorbable Barbed Bi-directional Surgical Suture”; Journal of Textile and Apparel, Technology and Management, vol. 2, Issue 2, Spring 2002, pp. 1-5. |
| Kostyuchenok, B.M., et al; “Vacuum Treatment in the Surgical Management of Purulent Wounds”; Vestnik Khirurgi, Sep. 1986, pp. 18-21 and 6 page English translation thereof. |
| Davydov, Yu. A., et al; “Vacuum Therapy in the Treatment of Purulent Lactation Mastitis”; Vestnik Khirurgi, May 14, 1986, pp. 66-70, and 9 page English translation thereof. |
| Yusupov. Yu. N., et al; “Active Wound Drainage”, Vestnik Khirurgi, vol. 138, Issue 4, 1987, and 7 page English translation thereof. |
| Davydov, Yu. A., et al; “Bacteriological and Cytological Assessment of Vacuum Therapy for Purulent Wounds”; Vestnik Khirurgi, Oct. 1988, pp. 48-52, and 8 page English translation thereof. |
| Davydov, Yu. A., et al; “Concepts for the Clinical-Biological Management of the Wound Process in the Treatment of Purulent Wounds by Means of Vacuum Therapy”; Vestnik Khirurgi, Jul. 7, 1980, pp. 132-136, and 8 page English translation thereof. |
| Chariker, Mark E., M.D., et al; “Effective Management of incisional and cutaneous fistulae with closed suction wound drainage”; Contemporary Surgery, vol. 34, Jun. 1989, pp. 59-63. |
| Egnell Minor, Instruction Book, First Edition, 300 7502, Feb. 1975, pp. 24. |
| Egnell Minor: Addition to the Users Manual Concerning Overflow Protection—Concerns all Egnell Pumps, Feb. 3, 1983, p. 1. |
| Svedman, P.: “Irrigation Treatment of Leg Ulcers”, The Lancet, Sep. 3, 1983, pp. 532-534. |
| Chinn, Steven D. et al.: “Closed Wound Suction Drainage”, The Journal of Foot Surgery, vol. 24, No. 1, 1985, pp. 76-81. |
| Arnljots, Björn et al.: “Irrigation Treatment in Split-Thickness Skin Grafting of Intractable Leg Ulcers”, Scand J. Plast Reconstr. Surg., vol. 19, 1985, pp. 211-213. |
| Svedman, P.: “A Dressing Allowing Continuous Treatment of a Biosurface”, IRCS Medical Science: Biomedical Technology, Clinical Medicine, Surgery and Transplantation, vol. 7, 1979, p. 221. |
| Svedman, P. et al.: “A Dressing System Providing Fluid Supply and Suction Drainage Used for Continuous or Intermittent Irrigation”, Annals of Plastic Surgery, vol. 17, No. 2, Aug. 1986, pp. 125-133. |
| K.F. Jeter, T.E. Tintle, and M. Chariker, “Managing Draining Wounds and Fistulae: New and Established Methods,” Chronic Wound Care, edited by D. Krasner (Health Management Publications, Inc., King of Prussia, PA 1990), pp. 240-246. |
| G. {hacek over (Z)}ivadinovic, V. ukic, {hacek over (Z)}. Maksimović, . Radak, and P. Pe{hacek over (s)}ka, “Vacuum Therapy in the Treatment of Peripheral Blood Vessels,” Timok Medical Journal 11 (1986), pp. 161-164 (copy and certified translation). |
| F.E. Johnson, “An Improved Technique for Skin Graft Placement Using a Suction Drain,” Surgery, Gynecology, and Obstetrics 159 (1984), pp. 584-585. |
| A.A. Safronov, Dissertation Abstract, Vacuum Therapy of Trophic Ulcers of the Lower Leg with Simultaneous Autoplasty of the Skin (Central Scientific Research Institute of Traumatology and Orthopedics, Moscow, U.S.S.R. 1967) (copy and certified translation). |
| M. Schein, R. Saadia, J.R. Jamieson, and G.A.G. Decker, “The ‘Sandwich Technique’ in the Management of the Open Abdomen,” British Journal of Surgery 73 (1986), pp. 369-370. |
| D.E. Tribble, “An Improved Sump Drain-Irrigation Device of Simple Construction,” Archives of Surgery 105 (1972) pp. 511-513. |
| C.E. Tennant, “The Use of Hypermia in the Postoperative Treatment of Lesions of the Extremities and Thorax,” Journal of the American Medical Association 64 (1915), pp. 1548-1549. |
| Selections from W. Meyer and V. Schmieden, Bier's Hyperemic Treatment in Surgery, Medicine, and the Specialties: A Manual of Its Practical Application, (W.B. Saunders Co., Philadelphia, PA 1909), pp. 17-25, 44-64, 90-96, 167-170, and 210-211. |
| V.A. Solovev et al., Guidelines, The Method of Treatment of Immature External Fistulas in the Upper Gastrointestinal Tract, editor-in-chief Prov. V.I. Parahonyak (S.M. Kirov Gorky State Medical Institute, Gorky, U.S.S.R. 1987) (“Solovev Guidelines”). |
| V.A. Kuznetsov & N.A. Bagautdinov, “Vacuum and Vacuum-Sorption Treatment of Open Septic Wounds,” in II All-Union Conference on Wounds and Wound Infections: Presentation Abstracts, edited by B.M. Kostyuchenok et al. (Moscow, U.S.S.R. Oct. 28-29, 1986) pp. 91-92 (“Bagautdinov II”). |
| V.A. Solovev, Dissertation Abstract, Treatment and Prevention of Suture Failures after Gastric Resection (S.M. Kirov Gorky State Medical Institute, Gorky, U.S.S.R. 1988) (“Solovev Abstract”). |
| V.A.C.® Therapy Clinical Guidelines: A Reference Source for Clinicians (Jul. 2007). |
| International Search Report and Written Opinion for corresponding PCT application PCT/US2016/051768 dated Dec. 15, 2016. |
| Number | Date | Country | |
|---|---|---|---|
| 20150057624 A1 | Feb 2015 | US |
| Number | Date | Country | |
|---|---|---|---|
| 61870080 | Aug 2013 | US |